- Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021.
- Adamis plans to appeal the FDA decision on ZIMHI and has requested a Type A meeting. If all goes well, we could see ZIMHI approved in the coming months.
- Recently, the company release back-to-back press releases announcing that they submitted TEMPOL's IND for COVID-19 and that Walgreen's has put SYMJEPI in their savings program for $99 for a two-pack.
- The share price moved from near 52-week lows to 52-week highs in a matter of a couple months. I booked some profits and will wait for the FDA's decision about ZIMHI before making another move.
For further details see:
Adamis Pharmaceuticals: Locking In Profits While Riding On The Back Of A Phoenix